CLINICAL TRIALS PROFILE FOR DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for doxylamine succinate; pyridoxine hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00293644 ↗ | Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy | Completed | Duchesnay Inc. | Phase 3 | 2006-02-01 | The purpose of this study is to determine whether pre-emptive use of a delayed release combination of pyridoxine hydrochloride and doxylamine succinate (Diclectin®), before eruption of symptoms of Nausea and vomiting of pregnancy and hyperemesis gravidarum, will reduce the incidence of severe forms of this syndrome/HG. |
| NCT00293644 ↗ | Pre-emptive Treatment of Severe Nausea and Vomiting of Pregnancy | Completed | The Hospital for Sick Children | Phase 3 | 2006-02-01 | The purpose of this study is to determine whether pre-emptive use of a delayed release combination of pyridoxine hydrochloride and doxylamine succinate (Diclectin®), before eruption of symptoms of Nausea and vomiting of pregnancy and hyperemesis gravidarum, will reduce the incidence of severe forms of this syndrome/HG. |
| NCT00614445 ↗ | The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy | Completed | Premier Research Group plc | Phase 3 | 2008-01-01 | The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a placebo. |
| NCT00614445 ↗ | The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy | Completed | Duchesnay Inc. | Phase 3 | 2008-01-01 | The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a placebo. |
| NCT03905564 ↗ | A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions | Withdrawn | Grünenthal, S.A. | Phase 1 | 2019-06-01 | The purpose of the study is to investigate any difference in the extent and rate of absorption of doxylamine between the test (investigational medicinal product [IMP]) and reference products that could impact the bioavailability of the medication when administered under fasting conditions. |
| NCT03905564 ↗ | A Study to Investigate Differences in the Extent and Rate of Absorption of Doxylamine/Pyridoxine From 2 Different Products Under Fasting Conditions | Withdrawn | Grünenthal GmbH | Phase 1 | 2019-06-01 | The purpose of the study is to investigate any difference in the extent and rate of absorption of doxylamine between the test (investigational medicinal product [IMP]) and reference products that could impact the bioavailability of the medication when administered under fasting conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for doxylamine succinate; pyridoxine hydrochloride
Condition Name
Clinical Trial Locations for doxylamine succinate; pyridoxine hydrochloride
Trials by Country
Clinical Trial Progress for doxylamine succinate; pyridoxine hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for doxylamine succinate; pyridoxine hydrochloride
Sponsor Name
